company background image
ROVI logo

Laboratorios Farmaceuticos Rovi BME:ROVI Stok Raporu

Son Fiyat

€79.90

Piyasa Değeri

€4.1b

7D

6.9%

1Y

67.8%

Güncellenmiş

03 Nov, 2024

Veri

Şirket Finansalları +

Laboratorios Farmaceuticos Rovi, S.A.

BME:ROVI Stok Raporu

Piyasa değeri: €4.1b

ROVI Stoklara Genel Bakış

Laboratorios Farmaceuticos Rovi, S.A. İspanya'da ve uluslararası alanda farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve pazarlanmasıyla ilgilenmektedir.

Laboratorios Farmaceuticos Rovi, S.A. Rakipler

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Laboratorios Farmaceuticos Rovi
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı€79.90
52 Haftanın En Yüksek Seviyesi€94.80
52 Haftanın En Düşük Seviyesi€46.78
Beta0.51
11 Aylık Değişim8.78%
3 Aylık Değişim3.90%
1 Yıllık Değişim67.79%
33 Yıllık Değişim40.42%
5 Yıllık Değişim224.80%
Halka arzdan bu yana değişim699.00%

Son Haberler & Güncellemeler

With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Recent updates

With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Oct 21
With Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) It Looks Like You'll Get What You Pay For

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Aug 29
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Jul 15
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Jun 17
We Take A Look At Why Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) CEO Has Earned Their Pay Packet

Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

May 08
Why We're Not Concerned About Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) Share Price

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Apr 17
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Feb 14
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 26% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Dec 21
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Nov 03
Is There An Opportunity With Laboratorios Farmaceuticos Rovi, S.A.'s (BME:ROVI) 34% Undervaluation?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Aug 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Quite Sensibly

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jul 14
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 27% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

May 26
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

May 05
Do Laboratorios Farmaceuticos Rovi's (BME:ROVI) Earnings Warrant Your Attention?

Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Apr 11
Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Shares Could Be 22% Below Their Intrinsic Value Estimate

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

Feb 22
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Have A Healthy Balance Sheet?

An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

Dec 10
An Intrinsic Calculation For Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Suggests It's 48% Undervalued

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Nov 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Safely

Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Sep 15
Does Laboratorios Farmaceuticos Rovi (BME:ROVI) Deserve A Spot On Your Watchlist?

Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Aug 28
Is Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI) Trading At A 41% Discount?

Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

Jun 15
Laboratorios Farmaceuticos Rovi (BME:ROVI) Seems To Use Debt Rather Sparingly

I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Feb 13
I Ran A Stock Scan For Earnings Growth And Laboratorios Farmaceuticos Rovi (BME:ROVI) Passed With Ease

Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

Jan 02
Is Laboratorios Farmaceuticos Rovi (BME:ROVI) A Risky Investment?

A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Dec 12
A Look At The Fair Value Of Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Nov 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Sep 24
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

Jun 02
Here's Why We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Well Worth Watching

We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Apr 06
We Think Laboratorios Farmaceuticos Rovi (BME:ROVI) Can Stay On Top Of Its Debt

Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

Mar 15
Investors Who Bought Laboratorios Farmaceuticos Rovi (BME:ROVI) Shares Five Years Ago Are Now Up 205%

If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Feb 16
If You Like EPS Growth Then Check Out Laboratorios Farmaceuticos Rovi (BME:ROVI) Before It's Too Late

Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

Jan 26
Are Strong Financial Prospects The Force That Is Driving The Momentum In Laboratorios Farmaceuticos Rovi, S.A.'s BME:ROVI) Stock?

These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Using Debt Reasonably Well

Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Dec 14
Announcing: Laboratorios Farmaceuticos Rovi (BME:ROVI) Stock Increased An Energizing 169% In The Last Five Years

Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Nov 26
Laboratorios Farmaceuticos Rovi (BME:ROVI) Is Growing Earnings But Are They A Good Guide?

Hissedar Getirileri

ROVIES PharmaceuticalsES Pazar
7D6.9%-2.4%0.02%
1Y67.8%12.6%25.3%

Getiri vs. Endüstri: ROVI geçen yıl % 12.6 oranında getiri sağlayan Spanish Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: ROVI geçen yıl % 25.3 oranında getiri sağlayan Spanish Piyasasını aştı.

Fiyat Oynaklığı

Is ROVI's price volatile compared to industry and market?
ROVI volatility
ROVI Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement5.2%
Market Average Movement2.9%
10% most volatile stocks in ES Market5.2%
10% least volatile stocks in ES Market0.6%

İstikrarlı Hisse Senedi Fiyatı: ROVI son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: ROVI 'nin haftalık oynaklığı ( 4% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
19462,137Juan Lopez-Belmonte Encinawww.rovi.es

Laboratorios Farmaceuticos Rovi, S.A., İspanya'da ve uluslararası alanda farmasötik ürünlerin araştırılması, geliştirilmesi, üretimi ve pazarlanması faaliyetlerini yürütmektedir. Şirket kardiyoloji, osteoartiküler/kadın sağlığı, anestezi/ağrı, tanısal görüntüleme kontrast ajanları, merkezi sinir sistemi, üroloji, endokrinoloji, solunum ve birinci basamak sağlık hizmetleri alanlarında ürünler sunmaktadır. Başlıca ürünleri arasında Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler ve Volutsa bulunmaktadır; ve Iomeron ve Iopamiro, Multihance ve Y Prohance, Sonovue, Empowercta+, Empowermr ve CT Express, Fibrilin ve Sodyum Heparin Rovi gibi hastane ürünleri.

Laboratorios Farmaceuticos Rovi, S.A. Temel Bilgiler Özeti

Laboratorios Farmaceuticos Rovi'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
ROVI temel i̇stati̇sti̇kler
Piyasa değeri€4.09b
Kazançlar(TTM)€148.03m
Gelir(TTM)€778.00m

27.6x

F/K Oranı

5.3x

P/S Oranı

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
ROVI gelir tablosu (TTM)
Gelir€778.00m
Gelir Maliyeti€316.13m
Brüt Kâr€461.87m
Diğer Giderler€313.83m
Kazançlar€148.03m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 07, 2024

Hisse başına kazanç (EPS)2.89
Brüt Marj59.37%
Net Kâr Marjı19.03%
Borç/Özkaynak Oranı21.5%

ROVI uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.4%

Mevcut Temettü Verimi

39%

Ödeme Oranı